ATE218884T1 - Impfstoffpräparate - Google Patents

Impfstoffpräparate

Info

Publication number
ATE218884T1
ATE218884T1 AT94903697T AT94903697T ATE218884T1 AT E218884 T1 ATE218884 T1 AT E218884T1 AT 94903697 T AT94903697 T AT 94903697T AT 94903697 T AT94903697 T AT 94903697T AT E218884 T1 ATE218884 T1 AT E218884T1
Authority
AT
Austria
Prior art keywords
vaccine preparations
immunogen
preparation comprises
release preparation
immediate
Prior art date
Application number
AT94903697T
Other languages
English (en)
Inventor
John Cooper Cox
Robert Edward Sparks
Irwin Clay Jacobs
Norbert Simon Mason
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21701000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE218884(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE218884T1 publication Critical patent/ATE218884T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT94903697T 1993-01-08 1993-12-24 Impfstoffpräparate ATE218884T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US248593A 1993-01-08 1993-01-08
PCT/AU1993/000677 WO1994015636A1 (en) 1993-01-08 1993-12-24 Vaccine preparations

Publications (1)

Publication Number Publication Date
ATE218884T1 true ATE218884T1 (de) 2002-06-15

Family

ID=21701000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903697T ATE218884T1 (de) 1993-01-08 1993-12-24 Impfstoffpräparate

Country Status (9)

Country Link
EP (1) EP0678035B9 (de)
JP (1) JP3583128B2 (de)
KR (1) KR100291357B1 (de)
AT (1) ATE218884T1 (de)
AU (1) AU667003B2 (de)
CA (1) CA2152949C (de)
DE (1) DE69332031T2 (de)
NZ (1) NZ259285A (de)
WO (1) WO1994015636A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM855194A0 (en) * 1994-10-04 1994-10-27 Csl Limited Controlled-release pharmaceutical preparations
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
EP1579851A3 (de) * 1997-08-29 2009-09-02 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben
US6312731B1 (en) * 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
WO2000012124A1 (en) 1998-09-01 2000-03-09 Elan Corporation, Plc Oral vaccine compositions
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
GB9906695D0 (en) * 1999-03-24 1999-05-19 Secr Defence Vaccine composition
US20050181063A1 (en) * 2000-03-22 2005-08-18 Alpar Hazire O. Pharmaceutical composition for administration to mucosal surfaces
JP2003535119A (ja) * 2000-06-08 2003-11-25 パウダージェクト ワクチンズ，インコーポレーテッド 粉末組成物
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
FR2825276B1 (fr) * 2001-05-31 2004-11-26 Seppic Sa Adujvant d'immunite sous forme solide et vaccin le contenant
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN102573802A (zh) * 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
WO2012038801A1 (en) * 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
US12447127B2 (en) 2011-05-17 2025-10-21 The Regents Of The University Of Colorado, A Body Corporate Thermostable vaccine compositions and methods of preparing the same
FR2977800B1 (fr) * 2011-07-13 2014-03-14 Sanofi Pasteur Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
CN119632954A (zh) * 2024-12-09 2025-03-18 中国人民解放军军事科学院军事医学研究院 一种颗粒载体缓释疫苗及其应用
CN120241585A (zh) * 2025-05-07 2025-07-04 长江大学 一种疫苗缓释埋植体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH645270A5 (en) * 1979-10-11 1984-09-28 Schweiz Serum & Impfinst Vaccine against coli bacillosis of piglets and process for its preparation
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
AU620149B2 (en) * 1988-08-18 1992-02-13 Vaxine Pty Ltd Gamma inulin compositions
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
WO1992010208A1 (en) * 1990-12-04 1992-06-25 Microtek Research And Development Ltd. Spray-dried antigenic products and method of preparation
EP0625069B1 (de) * 1992-10-26 1998-12-30 Schwarz Pharma Ag Verfahren zur herstellung von mikrokapseln

Also Published As

Publication number Publication date
JPH08505152A (ja) 1996-06-04
AU5805394A (en) 1994-08-15
EP0678035B1 (de) 2002-06-12
CA2152949A1 (en) 1994-07-21
NZ259285A (en) 1996-07-26
AU667003B2 (en) 1996-02-29
EP0678035B9 (de) 2006-12-13
CA2152949C (en) 2009-02-24
EP0678035A4 (de) 1997-02-26
DE69332031T2 (de) 2002-12-19
JP3583128B2 (ja) 2004-10-27
KR100291357B1 (ko) 2001-09-17
DE69332031D1 (de) 2002-07-18
KR960700070A (ko) 1996-01-19
WO1994015636A1 (en) 1994-07-21
EP0678035A1 (de) 1995-10-25

Similar Documents

Publication Publication Date Title
DE69332031D1 (de) Impfstoffpräparate
CA2064325A1 (en) External preparation for application to the skin containing lidocaine
DK0776885T3 (da) Biaromatiske forbindelser indeholdende en adamantylgruppe i positionen ortho, farmaceutiske og kosmetiske præparater, der i
ATE383165T1 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung, die wasserunlösliche komplexverbindungen enthalten
AU622526B2 (en) Sustained release pharmaceutical preparation
AU8366891A (en) Chewable spheroidal coated microcapsules and methods for preparing same
FI960042L (fi) Farmaseuttisia valmisteita niukkaliukoisia aktiivisia aineita varten
MY100721A (en) Therapeutic agent.
AU6147190A (en) An active matrix reflective projection system
FI955215A0 (fi) Hallitusti vapauttavat oksibutyniinivalmisteet
ATE183495T1 (de) 6-dimethylaminomethyl-1-phenyl-cyclo- hexanverbindungen als pharmazeutische wirkstoffe
DE59604226D1 (de) 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-olverbindungen als pharmazeutische Wirkstoffe
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
FI973278A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
DE122005000024I1 (de) Darifenacin enthaltende Pharmazeutische Zubereitungen.
FI973452A7 (fi) Nauhoitettu annosmuoto aktiivisen aineen pidennettyyn jakamiseen
NO974694D0 (no) Farmasöytisk preparat som inneholder N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus
EP0683671A4 (de) Modulationen des immunsystems mittels psoralene, die durch sichtbares licht aktiviert würden.
AU1245495A (en) Novel 2-arylalkenyl-azacycloalkane derivatives as sigma receptor ligands, preparation method therefor and therapeutical use thereof
AU8303691A (en) Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
DE69318153D1 (de) Antihypercholesterämisch-wirksame verbindungen, pharmazeutische präparate und verwendungen davon
ATE269695T1 (de) Pharmazeutische pellets
NO903347L (no) 14,17alfa-ethano- og ethanooestratriener, fremgangsmaate forfremstilling av disse forbindelser, saavel som anvendelse av dem for fremstilling av legemidler.
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties